Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin + megestrol acetate
- Development stage
- Unknown
- Lead developer
- University of Alabama at Birmingham
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The combination of paclitaxel, carboplatin, and megestrol acetate is an investigational chemo-hormonal regimen evaluated by the University of Alabama at Birmingham for the treatment of advanced-stage or recurrent endometrial cancer. This regimen integrates two standard cytotoxic chemotherapy agents with a hormonal therapy component. Paclitaxel is a taxane that stabilizes microtubules, thereby inhibiting cell division, while carboplatin is a platinum-based agent that induces DNA cross-linking and subsequent apoptosis. Megestrol acetate is a synthetic progestin that exerts anti-estrogenic effects on the endometrium, potentially sensitizing tumor cells or providing additive anti-tumor activity. This combination was primarily studied in a Phase II clinical trial (NCT00114608) to determine if adding hormonal modulation to standard chemotherapy could improve outcomes in patients with FIGO Stage III-IV or recurrent disease.
- Brand names
- TaxolMegaceParaplatin
- Other names
- Paclitaxel, Carboplatin and Megesterol AcetatePaclitaxel, Carboplatin and Megestrol Acetate
02
Targets
PR (Progesterone receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + carboplatin + megestrol acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin + megestrol acetate.